The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Targeting the mTOR pathway in hepatocellular carcinoma: Current state and future trends
Open accessAbstract
Mechanistic target of rapamycin (mTOR) regulates cell growth, metabolism and aging in response to nutrients, cellular energy stage and growth factors. mTOR is frequently up-regulated in cancer including hepatocellular carcinoma (HCC) and is associated with bad prognosis, poorly differentiated tumors, and earlier recurrence. Blocking mTOR with rapamycin and first generation mTOR inhibitors, called rapalogs, has shown promising reduction of HCC tumor growth in preclinical models. Currently, rapamycin/rapalogs are used in several clinical trials for the treatment of advanced HCC, and as adjuvant therapy in HCC patients after liver transplantation and TACE. A second generation of mTOR pathway inhibitors has been developed recently and is being tested in various clinical trials of solid cancers, and has been used in preclinical HCC models. The results of series of clinical trials using mTOR inhibitors in HCC treatment will emerge in the near future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832 · cited 2×
“65 months, which is similar to outcomes from single agent sorafenib in the SHARP trial, though superior to outcomes observed in an Asia-Pacific clinical trial [57,58].”
BackgroundResultSorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
European Association for the Study of the Liver (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.02.010 · Cited by 2,925
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast
Heitman, J., Movva, N. R., & Hall, M. N. (1991) · Science · doi:10.1126/science.1715094 · Cited by 2,006
Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling
Inoki, K., Li, Y., Xu, T., & Guan, K.-L. (2003) · Genes & Development · doi:10.1101/gad.1110003 · Cited by 1,911 · cited 1×
“The TSC1-TSC2 complex is a key regulator of mTORC1 and functions as a GTPase-activating protein (GAP) that negatively regulates Rheb by converting it into its inactive GDP-bound state [3,4].”
BackgroundGuichard, C., Amaddeo, G., Imbeaud, S., Ladeiro, Y., Pelletier, L., Maad, I. B., Calderaro, J., Bioulac-Sage, P., Letexier, M., Degos, F., et al. (2012) · Nature Genetics · doi:10.1038/ng.2256 · Cited by 1,453
Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34739 · Cited by 1,381
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets
Boyault, S., Rickman, D. S., de Reyniès, A., Balabaud, C., Rebouissou, S., Jeannot, E., Hérault, A., Saric, J., Belghiti, J., Franco, D., et al. (2007) · Hepatology · doi:10.1002/hep.21467 · Cited by 1,258
Hoshida, Y., Nijman, S. M. B., Kobayashi, M., Chan, J. A., Brunet, J.-P., Chiang, D. Y., Villanueva, A., Newell, P., Ikeda, K., Hashimoto, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1089 · Cited by 1,238 · cited 1×
“The G1/G2 patient subgroup was further confirmed in a large meta-analysis using integrative transcriptomics of 9 HCC data sets including a total of 603 patients [26].”
BackgroundCyclosporine induces cancer progression by a cell-autonomous mechanism
Hojo, M., Morimoto, T., Maluccio, M., Asano, T., Morimoto, K., Lagman, M., Shimbo, T., & Suthanthiran, M. (1999) · Nature · doi:10.1038/17401 · Cited by 1,149
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells
Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N., & Pollak, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1500 · Cited by 1,048
Rapamycin passes the torch: a new generation of mTOR inhibitors
Benjamin, D., Colombi, M., Moroni, C., & Hall, M. N. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3531 · Cited by 989
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells
Lee, J.-S., Heo, J., Libbrecht, L., Chu, I.-S., Kaposi-Novak, P., Calvisi, D. F., Mikaelyan, A., Roberts, L. R., Demetris, A. J., Sun, Z., et al. (2006) · Nature Medicine · doi:10.1038/nm1377 · Cited by 953
Self-citationClassification and prediction of survival in hepatocellular carcinoma by gene expression profiling
Lee, J.-S., Chu, I.-S., Heo, J., Calvisi, D. F., Sun, Z., Roskams, T., Durnez, A., Demetris, A. J., & Thorgeirsson, S. S. (2004) · Hepatology · doi:10.1002/hep.20375 · Cited by 922
Self-citationMetformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner
Kalender, A., Selvaraj, A., Kim, S. Y., Gulati, P., Brûlé, S., Viollet, B., Kemp, B. E., Bardeesy, N., Dennis, P., Schlager, J. J., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.03.014 · Cited by 889
Tee, A. R., Fingar, D. C., Manning, B. D., Kwiatkowski, D. J., Cantley, L. C., & Blenis, J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202476899 · Cited by 827 · cited 1×
“The TSC1-TSC2 complex is a key regulator of mTORC1 and functions as a GTPase-activating protein (GAP) that negatively regulates Rheb by converting it into its inactive GDP-bound state [3,4].”
BackgroundChoo, A. Y., Yoon, S.-O., Kim, S. G., Roux, P. P., & Blenis, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809136105 · Cited by 810
Autophagy as a target for anticancer therapy
Janku, F., McConkey, D. J., Hong, D. S., & Kurzrock, R. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.71 · Cited by 803
Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma
Villanueva, A., Chiang, D. Y., Newell, P., Peix, J., Thung, S., Alsinet, C., Tovar, V., Roayaie, S., Minguez, B., Sole, M., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.08.008 · Cited by 733
Focal Gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma
Chiang, D. Y., Villanueva, A., Hoshida, Y., Peix, J., Newell, P., Minguez, B., LeBlanc, A. C., Donovan, D. J., Thung, S. N., Solé, M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0742 · Cited by 719
DeYoung, M. P., Horak, P., Sofer, A., Sgroi, D., & Ellisen, L. W. (2008) · Genes & Development · doi:10.1101/gad.1617608 · Cited by 710 · cited 1×
“In contrast, down-regulation of mTORC1, is accomplished via activation of the TSC1-TSC2 complex by AMPK, LKB1, and REDD1 in situations of low energy (high AMP), low oxygen levels [5], and DNA damage [6].”
BackgroundHepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas
Horie, Y., Suzuki, A., Kataoka, E., Sasaki, T., Hamada, K., Sasaki, J., Mizuno, K., Hasegawa, G., Kishimoto, H., Iizuka, M., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420513 · Cited by 698
Genome Sequencing Identifies a Basis for Everolimus Sensitivity
Iyer, G., Hanrahan, A. J., Milowsky, M. I., Al-Ahmadie, H., Scott, S. N., Janakiraman, M., Pirun, M., Sander, C., Socci, N. D., Ostrovnaya, I., et al. (2012) · Science · doi:10.1126/science.1226344 · Cited by 690
Bendell, J. C., Rodon, J., Burris, H. A., de Jonge, M., Verweij, J., Birle, D., Demanse, D., De Buck, S. S., Ru, Q. C., Peters, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1360 · Cited by 684
Activation of mTORC2 by Association with the Ribosome
Zinzalla, V., Stracka, D., Oppliger, W., & Hall, M. N. (2011) · Cell · doi:10.1016/j.cell.2011.02.014 · Cited by 654
Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1
Ben Sahra, I., Regazzetti, C., Robert, G., Laurent, K., Le Marchand-Brustel, Y., Auberger, P., Tanti, J.-F., Giorgetti-Peraldi, S., & Bost, F. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1769 · Cited by 616
Calvisi, D. F., Wang, C., Ho, C., Ladu, S., Lee, S. A., Mattu, S., Destefanis, G., Delogu, S., Zimmermann, A., Ericsson, J., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.12.006 · Cited by 595
Andersen, J. B., Spee, B., Blechacz, B. R., Avital, I., Komuta, M., Barbour, A., Conner, E. A., Gillen, M. C., Roskams, T., Roberts, L. R., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.005 · Cited by 552
Self-citationYap, T. A., Yan, L., Patnaik, A., Fearen, I., Olmos, D., Papadopoulos, K., Baird, R. D., Delgado, L., Taylor, A., Lupinacci, L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5263 · Cited by 539
Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma
Kan, Z., Zheng, H., Liu, X., Li, S., Barber, T. D., Gong, Z., Gao, H., Hao, K., Willard, M. D., Xu, J., et al. (2013) · Genome Research · doi:10.1101/gr.154492.113 · Cited by 523
Metabolic syndrome and hepatocellular carcinoma: Two growing epidemics with a potential link
Siegel, A. B., & Zhu, A. X. (2009) · Cancer · doi:10.1002/cncr.24687 · Cited by 399
Chen, H.-P., Shieh, J.-J., Chang, C.-C., Chen, T.-T., Lin, J.-T., Wu, M.-S., Lin, J.-H., & Wu, C.-Y. (2013) · Gut · doi:10.1136/gutjnl-2011-301708 · Cited by 392
mTOR and P70 S6 Kinase Expression in Primary Liver Neoplasms
Sahin, F., Kannangai, R., Adegbola, O., Wang, J., Su, G., & Torbenson, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0941 · Cited by 382
Xia, H., Ooi, L. L. P. J., & Hui, K. M. (2013) · Hepatology · doi:10.1002/hep.26369 · Cited by 378
Di Nicolantonio, F., Arena, S., Tabernero, J., Grosso, S., Molinari, F., Macarulla, T., Russo, M., Cancelliere, C., Zecchin, D., Mazzucchelli, L., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci37539 · Cited by 343
A Hepatocellular Carcinoma 5-Gene Score Associated With Survival of Patients After Liver Resection
Nault, J., De Reyniès, A., Villanueva, A., Calderaro, J., Rebouissou, S., Couchy, G., Decaens, T., Franco, D., Imbeaud, S., Rousseau, F., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.03.051 · Cited by 338
Self-citationCommon corruption of the mTOR signaling network in human tumors
Menon, S., & Manning, B. D. (2008) · Oncogene · doi:10.1038/onc.2009.352 · Cited by 332
Chen, K.-F., Chen, H.-L., Tai, W.-T., Feng, W.-C., Hsu, C.-H., Chen, P.-J., & Cheng, A.-L. (2011) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.175786 · Cited by 317
Identification of driver genes in hepatocellular carcinoma by exome sequencing
Cleary, S. P., Jeck, W. R., Zhao, X., Chen, K., Selitsky, S. R., Savich, G. L., Tan, T.-X., Wu, M. C., Getz, G., Lawrence, M. S., et al. (2013) · Hepatology · doi:10.1002/hep.26540 · Cited by 302
Zhang, Z.-J., Zheng, Z.-J., Shi, R., Su, Q., Jiang, Q., & Kip, K. E. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1267 · Cited by 241
The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma
Zhou, L., Huang, Y., Li, J., & Wang, Z. (2010) · Medical Oncology · doi:10.1007/s12032-009-9201-4 · Cited by 225
Semela, D., Piguet, A.-C., Kolev, M., Schmitter, K., Hlushchuk, R., Djonov, V., Stoupis, C., & Dufour, J.-F. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2006.11.021 · Cited by 225
Newell, P., Toffanin, S., Villanueva, A., Chiang, D. Y., Minguez, B., Cabellos, L., Savic, R., Hoshida, Y., Lim, K. H., Melgar-Lesmes, P., et al. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.03.028 · Cited by 222
Zheng, L., Yang, W., Wu, F., Wang, C., Yu, L., Tang, L., Qiu, B., Li, Y., Guo, L., Wu, M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0203 · Cited by 221
Distinct perturbation of the translatome by the antidiabetic drug metformin
Larsson, O., Morita, M., Topisirovic, I., Alain, T., Blouin, M.-J., Pollak, M., & Sonenberg, N. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201689109 · Cited by 205
Phase 1/2 study of everolimus in advanced hepatocellular carcinoma
Zhu, A. X., Abrams, T. A., Miksad, R., Blaszkowsky, L. S., Meyerhardt, J. A., Zheng, H., Muzikansky, A., Clark, J. W., Kwak, E. L., Schrag, D., et al. (2011) · Cancer · doi:10.1002/cncr.26165 · Cited by 197
Chronic Activation of mTOR Complex 1 Is Sufficient to Cause Hepatocellular Carcinoma in Mice
Menon, S., Yecies, J. L., Zhang, H. H., Howell, J. J., Nicholatos, J., Harputlugil, E., Bronson, R. T., Kwiatkowski, D. J., & Manning, B. D. (2012) · Science Signaling · doi:10.1126/scisignal.2002739 · Cited by 182
Phoenix, K. N., Vumbaca, F., & Claffey, K. P. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-9916-5 · Cited by 173
Lee, J.-S., & Thorgeirsson, S. S. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.015 · Cited by 173
Self-citationHong, D. S., Bowles, D. W., Falchook, G. S., Messersmith, W. A., George, G. C., O'Bryant, C. L., Vo, A. C. H., Klucher, K., Herbst, R. S., Eckhardt, S. G., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0714 · Cited by 169
Liang, W., Wang, D., Ling, X., Allen Kao, A., Kong, Y., Shang, Y., Guo, Z., & He, X. (2012) · Liver Transplantation · doi:10.1002/lt.22441 · Cited by 164
Sieghart, W., Fuereder, T., Schmid, K., Cejka, D., Werzowa, J. M., Wrba, F., Wang, X., Gruber, D., Rasoul‐Rockenschaub, S., Peck‐Radosavljevic, M., et al. (2007) · Transplantation · doi:10.1097/01.tp.0000252780.42104.95 · Cited by 163
Van Ummersen, L., Binger, K., Volkman, J., Marnocha, R., Tutsch, K., Kolesar, J., Arzoomanian, R., Alberti, D., & Wilding, G. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0406 · Cited by 158
Markman, B., Tabernero, J. M., Krop, I. E., Shapiro, G. I., Siu, L. L., Chen, L. C., Mita, M. M., Cuero, M. M., Stutvoet, S., Birle, D. C., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds011 · Cited by 158
Metformin Accelerates the Growth of BRAFV600E-Driven Melanoma by Upregulating VEGF-A
Martin, M. J., Hayward, R., Virós, A., & Marais, R. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0280 · Cited by 152
Wang, Z., Zhou, J. P., Fan, J., Qiu, S., Yao, Y., Huang, X., & Tang, Z. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4774 · Cited by 144
Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer
Rizell, M., Andersson, M., Cahlin, C., Hafström, L., Olausson, M., & Lindnér, P. (2008) · International Journal of Clinical Oncology · doi:10.1007/s10147-007-0733-3 · Cited by 142
Neef, M., Ledermann, M., Saegesser, H., Schneider, V., & Reichen, J. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.07.030 · Cited by 140
Mahadevan, D., Chiorean, E. G., Harris, W. B., Hoff, D. D. V., Stejskal-Barnett, A., Qi, W., Anthony, S. P., Younger, A., Rensvold, D., Cordova-Marks, F. M., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.06.027 · Cited by 138
Naing, A., Aghajanian, C. A., Raymond, É., Olmos, D., Schwartz, G., Oelmann, E. M., Grinsted, L. M., Burke, W., Taylor, R., Kaye, S. B., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.368 · Cited by 138
The role of autophagy in liver cancer: Molecular mechanisms and potential therapeutic targets
Cui, J., Gong, Z., & Shen, H. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.02.003 · Cited by 130
Grabinski, N., Ewald, F., Hofmann, B. T., Staufer, K., Schumacher, U., Nashan, B., & Jücker, M. (2012) · Molecular Cancer · doi:10.1186/1476-4598-11-85 · Cited by 129
Patsenker, E., Schneider, V., Ledermann, M., Saegesser, H., Dorn, C., Hellerbrand, C., & Stickel, F. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.10.044 · Cited by 123
Label-retaining liver cancer cells are relatively resistant to sorafenib
Xin, H.-W., Ambe, C. M., Hari, D. M., Wiegand, G. W., Miller, T. C., Chen, J., Anderson, A. J., Ray, S., Mullinax, J. E., Koizumi, T., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-303261 · Cited by 111
Self-citationIdentification of Potential Driver Genes in Human Liver Carcinoma by Genomewide Screening
Woo, H. G., Park, E. S., Lee, J., Lee, Y.-H., Ishikawa, T., Kim, Y. J., & Thorgeirsson, S. S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0164 · Cited by 105
Self-citationDucker, G. S., Atreya, C. E., Simko, J. P., Hom, Y. K., Matli, M. R., Benes, C. H., Hann, B. C., Nakakura, E. K., Bergsland, E. K., Donner, D. B., et al. (2013) · Oncogene · doi:10.1038/onc.2013.92 · Cited by 101
Gedaly, R., Angulo, P., Hundley, J. C., Daily, M. F., Chen, C., & Evers, B. M. (2011) · Journal of Surgical Research · doi:10.1016/j.jss.2011.10.045 · Cited by 100
Thomas, H. E., Mercer, C. A., Carnevalli, L. S., Park, J., Andersen, J. B., Conner, E. A., Tanaka, K., Matsutani, T., Iwanami, A., Aronow, B. J., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003923 · Cited by 98
Self-citationPiguet, A., Saar, B., Hlushchuk, R., St–Pierre, M. V., McSheehy, P. M. J., Radojevic, V., Afthinos, M., Terracciano, L., Djonov, V., & Dufour, J. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0666 · Cited by 86
Diagnosis and management of chronic hepatitis C virus infection
Gordon, S. (2004) · CRC Press eBooks · doi:10.1201/b13913-6 · Cited by 86
Freise, C. E., Ferrell, L. D., Liu, T., Ascher, N. L., & Roberts, J. P. (1999) · Transplantation · doi:10.1097/00007890-199902270-00003 · Cited by 85
Garrett, C. R., Coppola, D., Wenham, R. M., Cubitt, C. L., Neuger, A. M., Frost, T. J., Lush, R. M., Sullivan, D. M., Cheng, J. Q., & Sebti, S. M. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9479-2 · Cited by 79
de Aguirre, Boya, P., Bellet, D. H., Faivre, S. J., Troalen, F., Bénard, J., Saulnier, P., Hopkins-Donaldson, S., Zangemeister‐Wittke, U., Kroemer, G., et al. (2004) · APOPTOSIS · doi:10.1023/b:appt.0000045781.46314.e2 · Cited by 78
Petrich, A. M., Leshchenko, V. V., Kuo, P.-Y., Xia, B., Thirukonda, V. K., Ulahannan, N., Gordon, S. A. K., Fazzari, M. J., Ye, B. H., Sparano, J. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1407 · Cited by 72
Phase II study of sirolimus in treatment-naive patients with advanced hepatocellular carcinoma
Decaens, T., Luciani, A., Itti, E., Lesne-Hulin, A., Roudot‐Thoraval, F., Laurent, A., Zafrani, É. S., Mallat, A., & Duvoux, C. (2012) · Digestive and Liver Disease · doi:10.1016/j.dld.2012.02.005 · Cited by 69
Self-citationShiah, H.-S., Chen, C., Dai, C., Hsiao, C., Lin, Y., Su, W., Chang, J. ‐., Whang‐Peng, J., Lin, P. W., Huang, J., et al. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12132 · Cited by 67
Akt and mTORC1 Have Different Roles During Liver Tumorigenesis in Mice
Kenerson, H. L., Yeh, M. M., Kazami, M., Jiang, X., Riehle, K. J., McIntyre, R. L., Park, J. O., Kwon, S., Campbell, J. S., & Yeung, R. S. W. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.01.053 · Cited by 65
Evert, M., Calvisi, D. F., Evert, K., Murtas, V. D., Gasparetti, G., Mattu, S., Destefanis, G., Ladu, S., Zimmermann, A., Delogu, S., et al. (2012) · Hepatology · doi:10.1002/hep.25600 · Cited by 61
Kelley, R. K., Nimeiri, H. S., Münster, P. N., Vergo, M. T., Huang, Y., Li, C., Hwang, J. H., Mulcahy, M. F., Yeh, B. M., Kühn, P., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt109 · Cited by 58
Reprogramming of the MicroRNA Transcriptome Mediates Resistance to Rapamycin
Totary-Jain, H., Sanoudou, D., Ben‐Dov, I. Z., Dautriche, C. N., Guarnieri, P., Marx, S. O., Tuschl, T., & Marks, A. R. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.416446 · Cited by 48
Baba, H. A., Wohlschlaeger, J., Cicinnati, V. R., Hilgard, P. A., Lang, H., Sotiropoulos, G. C., Takeda, A., Beckebaum, S., & Schmitz, K. J. (2009) · Liver International · doi:10.1111/j.1478-3231.2008.01798.x · Cited by 48
Buitrago‐Molina, L. E., Pothiraju, D., Lamlé, J., Marhenke, S., Kossatz-Boehlert, U., Breuhahn, K., Manns, M. P., Malek, N. P., & Vogel, A. (2009) · Hepatology · doi:10.1002/hep.23014 · Cited by 48
Colombo, M., Raoul, J., Lencioni, R. A., Galle, P. R., Zucman‐Rossi, J., Bañares, R., Seehofer, D., Neuhaus, P., & Johnson, P. J. (2013) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e32835e33bb · Cited by 47
Kirstein, M. M., Boukouris, A. E., Pothiraju, D., Buitrago‐Molina, L. E., Marhenke, S., Schuett, J., Orlik, J., Kühnel, F., Hegermann, J., Manns, M. P., et al. (2013) · Liver International · doi:10.1111/liv.12126 · Cited by 46
Serova, M., Gramont, A. D. E., Tijeras‐Raballand, A., Santos, C. D., Riveiro, M. E., Slimane, K., Faivre, S. J., & Raymond, É. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2129-6 · Cited by 43
Parent, R., Kolippakkam, D. N., Booth, G. C., & Beretta, L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3640 · Cited by 41
Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors
Delbaldo, C., Albert, S., Dreyer, C., Sablin, M., Serova, M., Raymond, É., & Faivre, S. J. (2011) · Targeted Oncology · doi:10.1007/s11523-011-0177-6 · Cited by 37
Regulation of Gene Expression in Hepatic Cells by the Mammalian Target of Rapamycin (mTOR)
Jimenez, R. H., Lee, J., Francesconi, M., Castellani, G., Neretti, N., Sanders, J. A., Sedivy, J. M., & Gruppuso, P. A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009084 · Cited by 31
mTOR as a Potential Target for the Prevention and Treatment of Hepatocellular Carcinoma
Buitrago‐Molina, L. E., & Vogel, A. (2012) · Current Cancer Drug Targets · doi:10.2174/156800912803988011 · Cited by 27
Pilot study: rapamycin in advanced hepatocellular carcinoma
Schöniger–Hekele, M., & Müller, C. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04404.x · Cited by 24
Rapamycin Response in Tumorigenic and Non-Tumorigenic Hepatic Cell Lines
Jimenez, R. H., Boylan, J. M., Lee, J., Francesconi, M., Castellani, G., Sanders, J. A., & Gruppuso, P. A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007373 · Cited by 24
Choo, S. P., Chowbay, B., Ng, Q. S., Thng, C. H., Lim, C., Hartono, S., Koh, T. S., Huynh, H. T., Poon, D., Ang, M., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.11.008 · Cited by 23
Wu, N., Gu, H., & Li, Q. (2010) · Europe PMC (PubMed Central) · Cited by 13
Markers for efficacy of mammalian target of rapamycin inhibitor.
Liao, Y. M., Sy, A., & Yen, Y. (2012) · PubMed · Cited by 7
Cited by
Molecular therapies and precision medicine for hepatocellular carcinoma
Llovet, J. M., Montal, R., Sia, D., & Finn, R. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0073-4 · Cited by 1,938
From NASH to HCC: current concepts and future challenges
Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O., & Heikenwalder, M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0145-7 · Cited by 1,392
EASL Clinical Practice Guidelines: Liver transplantation
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.10.006 · Cited by 1,082
Mehta, N., Heimbach, J., Harnois, D. M., Sapisochin, G., Dodge, J. L., Lee, D., Burns, J. M., Sanchez, W., Greig, P. D., Grant, D. R., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5116 · Cited by 398
β-Catenin signaling in hepatocellular carcinoma
Xu, C., Xu, Z., Zhang, Y., Evert, M., Calvisi, D. F., & Chen, X. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154515 · Cited by 305
Metadata
- Authors
- Matter, M. S., Decaens, T., Andersen, J. B., & Thorgeirsson, S. S.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2014-04
- Volume
- 60
- Issue
- 4
- Pages
- 855-865
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2018992554
- Cited by
- 314
- References
- 98
- FWCI
- 6.59
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.